Juan Pablo Ospina Botero, MD
Medical Oncology

Juan Pablo Ospina Botero, MD

Medical Oncology
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Neurology

My education and training

  • Universidad De Los Andes ColombiaMedical School
  • University of Chicago Medical CenterResidency
  • Massachusetts General Hospital, Dana-Farber Cancer Institute, and Brigham and Women's HospitalFellowship

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Ospina Botero is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Michael A. Perez, Jacob Sunnerberg, Cole Friedes, Goldie Kurtz, Jay F. Dorsey, Arati Desai, MacLean Nasrallah, Nduka M. Amankulor, Christina Jackson, Donald M. O’Rourke, Ali Nabavizadeh, Suyash Mohan, Hamed Akbari, Christos Davatzikos, Juan Pablo Ospina, Harper Hubbeling, Michelle Alonso-Basanta, Richard E. Phillips, Emily S. Lebow, Stephen J. Bagley Evaluating the Prevalence of Radiation Necrosis Among Patients with IDH-mutant Grade 2 and 3 Gliomas Receiving Proton or Photon Radiotherapy at Diagnosis , Neuro-Oncology: 2026


Sanjeev Chawla, Archith Rajan, Laiz Laura de Godoy, Sulaiman Sheriff, Kristina Vineis, Demetrius Lee, Fred Miglo, Lisa Desiderio, Atom Sarkar, Rinku Shah, Dawit Aregawi, Tara Morrison, Srilatha Hosur, Sunjay Shah, Gaurav Shukla, Varsha Jain, Scott Herbert, Nduka Amankulor, Stephanie Weiss, Anshu Giri, Aruna Padmanabhan, Anthony Ricco, Iyad Alnahhas, Linna Li, Eric Hintz, Ami Raval, Bonnie Shetler, Elizabeth Heisler, Juan Pablo Ospina, Emily Lebow, Stephen Bagley, Suyash Mohan Mapping the Metabolic Maze: How Whole-Brain Spectroscopic Imaging Redefines Target Volume and Significantly Alters TTFields Dosimetry in Glioblastoma , Neuro-Oncology: 2026


Jacob Sunnerberg, Cole Friedes, Michael Perez, Yin Gao, Melanie Berger, Lauren Linkowski, Haelee Chin, Goldie Kurtz, Harper Hubbeling, Jay F. Dorsey MSCE, Robert A. Lustig, Arati Desai, Juan Pablo Ospina, MacLean Nasrallah, Nduka M. Amankulor, Christina Jackson, Ali Nabavizadeh, Hamed Akbari, Christos Davatzikos, Donald M. O'Rourke, Suyash Mohan, Michelle Alonso-Basanta, Kevin Teo, Stephen J. Bagley, Emily S. Lebow Clinical and Dosimetric Predictors of Symptomatic Radiation Necrosis in IDH-Mutant Grade 3 Glioma: A Single-Institution Cohort Study with Comprehensive Dose-Volume Analysis , Neuro-Oncology: 2026


Julien Rousseau*, Prem S. Prabhakar*, Juan Pablo Ospina*, Ian Pan*, Catharina C. Westergaard, Lorenzo Trippa, Vihang Nakhate, Raymond Y. Huang, Alyssa Russ, Rachel Fox, Ernest Wang, Elisa Aquilanti, Tamar R. Berger, Rameen Beroukhim, L. Nicolas Gonzalez Castro, Lakshmi Nayak, John Y. Rhee, David A. Reardon, Ugonma N. Chukwueke, Keith L. Ligon#, Gilbert Youssef#, Patrick Y. Wen Molecular Subgroups And Genomic Clusters Define Distinct Survival Trajectories In IDH-Wildtype Glioblastoma , Neuro-Oncology: 2026


Melanie Berger MD, Cole Friedes MD, Lauren Linkowski MD, Casey Hollawell MD, Ian Messing MD, Matthew Riina MD, Jacob Sunnerberg PhD, Megan Lee MS, Goldie Kurtz MD, Jay F. Dorsey MD PhD MSCE, Arati Desai MD, MacLean Nasrallah MD PhD, Ali Nabavizadeh MD, Suyash Mohan MD, Hamed Akbari MD, PhD, Christos Davatzikos PhD, Nduka M. Amankulor MD, Christina Jackson MD, Donald M. O’Rourke MD, Zev A. Binder MD, PhD, Juan Pablo Ospina MD, Stephen J. Bagley MD, Harper Hubbeling MD, Michelle Alonso-Basanta MD PhD, Emily S. Lebow MD Menopausal Status and Risk of Severe Radiation-Induced Lymphopenia in Glioblastoma , Neuro-Oncology: 2026


Sanjeev Chawla, Archith Rajan, Laiz Laura de Godoy, Sulaiman Sheriff, Kristina Vineis, Demetrius Lee, Fred Miglo, Lisa Desiderio, Atom Sarkar, Rinku Shah, Dawit Aregawi, Tara Morrison, Srilatha Hosur, Sunjay Shah, Gaurav Shukla, Varsha Jain, Scott Herbert, Nduka Amankulor, Stephanie Weiss, Anshu Giri, Aruna Padmanabhan, Elizabeth Heisler, Juan Pablo Ospina, Emily Lebow, Stephen Bagley, Suyash Mohan. Tumor Treating Fields in Glioblastoma: Anatomical vs Metabolic Imaging Guided Targeting and Impact on Dosimetry Profiles , ISMRM Workshop on Translational Cancer Imaging: From Acronym to Actuality: 2026


Youssef G, Aquilanti E, Miller JJ, Lan Z, Lasica AB, Arrillaga-Romany I, Batchelor TT, Berger TR, Beroukhim R, Chukwueke U, Dietrich J, Forst DA, Gerstner ER, Castro LNG, Jordan JT, Mcfaline-Figueroa JR, Lee EQ, Nayak L, Nakhate V, Ospina JP, Plotkin SR, Wang N, Rhee JY, Reardon DA, Wen PY. Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma , Neuro Oncology, 28: 2026,752-764


Koga S, Nasrallah IM, Blue R, Ospina JP, Brem S, Shpilsky J, Nasrallah M, Mourelatos Z. Metachronous Pineal Germinoma 11 Years After Total Resection of a Mature Teratoma , Neuropathology: 2026


Khushboo Verma, MD; Jonathan Perkins, MD; Vivian J. Dickens, MD; Matthew Boden, MD; Darshil Shah, MD; Stephen Bagley, MD, MSCE; Christina Jackson, MD; Emily Schapira Lebow, MD; Juan Pablo Ospina, MD CNS Tumors And Related Complications For The Neuro-Critical Care Physician , Neurocritical Care Foundations: 2026


Lasica A, Lan Z, Miller J, Russ A, Westergaard C, Lee E, Chukwueke U, Gonzalez Castro L, McFaline Figueroa J, Aquilanti E, Nayak L, Beroukhim R, Batchelor T, Nakhate V, Lanman T, Ospina JP, Stec N, Reardon D, Wen P, Youssef G Clinical and radiographic predictors of prognosis in astrocytoma, IDH-mutant, WHO grade 4 , Neuro-Oncology: 2025